Jeffrey W. Miller

A decade of innovation in pharmaceutical R&D: the Chorus model

P. K. Owens, Paul K. Owens, Eyas Raddad, 2014, Nature Reviews Drug Discovery.

Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes

Andrea De Gaetano, A. De Gaetano, E. Abu-Raddad, 2013, Diabetes Care.

Double-Blind , Randomized Study Evaluating the Glycemic and Anti-in fl ammatory Effects of Subcutaneous LY 2189102 , a Neutralizing IL-1 b Antibody , in PatientsWith Type 2 Diabetes

E. Abu-Raddad, A. Gaetano, W. Landschulz, 2013 .

LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase

J. Sloan-Lancaster, Jeffrey W. Miller, E. Raddad, 2017, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Modulation of blood pressure by central melanocortinergic pathways.

S. O’Rahilly, S. Brage, D. Lomas, 2009, The New England journal of medicine.

Expression of α 1 adrenergic receptor subtype mRNAs in the rat cardiovascular system with aging

Jeffrey W. Miller, Zhuo-wei Hu, B. Hoffman, 1996, Mechanisms of Ageing and Development.

Divergent Effects of Raloxifene HCl on the the Pharmacokinetics and Pharmacodynamics of Warfarin

Atalanta Ghosh, S. Allerheiligen, Jeffrey W. Miller, 2001, Pharmaceutical Research.

Induction of Enhanced Release of Endothelium‐Derived Relaxing Factor After Prolonged Exposure to a‐Adrenergic Agonists: Role in Desensitization of Smooth Muscle Contraction

Jeffrey W. Miller, Zhuo-wei Hu, B. Hoffman, 1994, Journal of cardiovascular pharmacology.